| EN

Endostar®:Recombinant human endostatin injection

Endostar®:Recombinant human endostatin injection

Indications:

Indications: Used in combination with NP chemotherapy regimen for the treatment of early and recurrent Stage III/IV NSCLC.

 

Endostar® is clinically proven to be less toxic than conventional chemotherapy drugs and able to significantly extend advanced NSCLC patients’ median survival time and quality of life.

Recombinant human endostatin is recommended as a first-line treatment for advanced NSCLC patients by a number of oncology clinical practice guidelines issued by the NHC, Chinese Medical Association (中华医学会) and CSCO.

In addition, Endostar® has also shown superior efficacy in treatment of certain other tumors and complications, such as melanoma, osteosarcoma and malignant pleural effusion, and received wide recognition among healthcare professionals. Recombinant human endostatin is recommended as a first-line therapy for malignant melanoma and osteosarcoma by relevant clinical practice guidelines issued by CSCO.

Endostar®—Recombinant human endostatin has been included in the NRDL since 2017.